首頁 > 市場調查報告書 > 醫療設備

醫學影像診斷核子醫學

市場調查報告書

商品編碼

1708113

放射性藥物：技術與全球市場

Radiopharmaceuticals: Technologies and Global Markets

出版日期: 2025年04月10日 | 出版商:

BCC Research | 英文 163 Pages | 訂單完成後即時交付

價格

簡介目錄圖表

預計到 2029 年底，全球放射性藥物市場規模將從 2024 年的 103 億美元增加到 219 億美元，預測期內的複合年成長率為 16.4%。

預計北美市場將從 2024 年的 49 億美元成長到 2029 年底的 115 億美元，預測期內的複合年成長率為 18.5%。預計歐洲市場將從 2024 年的 23 億美元成長到 2029 年底的 49 億美元，複合年成長率為 16.4%。

本報告調查了全球放射性藥物市場，並提供了市場概況的摘要、市場影響因素和市場機會的分析、法律制度、新興技術和技術發展的趨勢、市場規模的趨勢和預測、各個細分市場和地區的詳細分析、競爭格局以及主要企業的概況。

市場促進因素
癌症和其他慢性病發生率上升
腫瘤學領域未被滿足的需求
精準醫療
核子成像技術
增加投資
市場限制
製造和供應鏈問題
基礎設施和特殊成像設備需求
專業技能人才短缺
市場趨勢
治療診斷學
區域多樣化和供應鏈彈性
機會
放射性藥物契約製造
PET 影像在 AD 的應用

第4章監管情況

美國
EU
日本

第5章新興技術與發展

新興技術
Ac-225 和 Pb-212
基於奈米顆粒的治療診斷藥物
臨床試驗分析
診斷放射性藥物
治療性放射性藥物
專利分析
關鍵要點

第6章市場區隔分析

細分市場
放射性藥物市場（依產品類型）
診斷
按成像技術類型進行診斷
用於診斷：按製造方法
治療
治療：依產品類型
放射性藥物市場（依應用）
市場概覽
瘤
心臟病
神經
其他
按製造方法分類的放射性藥物市場
市場概覽
市場收益和預測
地理分佈
放射性藥物市場（按地區）
北美洲
歐洲
亞太地區
其他地區

第7章競爭訊息

概述
診斷放射性藥物
治療性放射性藥物

第8章放射性藥物市場的永續性：ESG 視角

ESG在放射性製藥產業中的作用
環境
社會
管治
ESG風險評估
結論

第9章附錄

調查方法
來源
簡稱
公司簡介
BAYER AG
BLUE EARTH DIAGNOSTICS
BOSTON SCIENTIFIC CORP.
BWXT MEDICAL LTD.
CARDINAL HEALTH
CURIUM
ECKERT & ZIEGLER
GE HEALTHCARE
INTERNATIONAL ISOTOPES INC.
IONETIX CORP.
JUBILANT PHARMOVA LTD.
LANTHEUS
NMR
NOVARTIS AG
SIEMENS HEATHNIEERS AG
新興Start-Ups/市場顛覆者

簡介目錄圖表

Product Code: PHM171C

The global radiopharmaceuticals market is expected to grow from $10.3 billion in 2024 and is projected to reach $21.9 billion by the end of 2029, at a compound annual growth rate (CAGR) of 16.4% during the forecast period of 2024 to 2029.

The North American radiopharmaceuticals market is expected to grow from $4.9 billion in 2024 and is projected to reach $11.5 billion by the end of 2029, at a CAGR of 18.5% during the forecast period of 2024 to 2029.

The European radiopharmaceuticals market is expected to grow from $2.3 billion in 2024 and is projected to reach $4.9 billion by the end of 2029, at a CAGR of 16.4% during the forecast period of 2024 to 2029.

Report Scope

This report analyzes the global market for radiopharmaceuticals, in terms of quantitative and qualitative data, to help readers understand the market, to assess business/growth strategies, and to make informed business decisions regarding radiopharmaceuticals. BCC Research estimates market data for 2023 (the base year) and 2024 and forecasts values for 2025 through 2029. The radiopharmaceuticals market segmentation is based on product, application, production method, countries and regions.

Drivers, restraints and opportunities in the radiopharmaceuticals market are also discussed. The report also describes the competitive landscape of the radiopharmaceuticals market and highlights emerging trends. The latest new products, acquisitions, and collaborations related to the radiopharmaceuticals market are also covered.

Report Includes

50 data tables and 68 additional tables
Analyses of trends in the global market for radiopharmaceuticals, with revenue data for 2021 to 2023, estimates for 2024, and projected CAGRs through 2029
Estimates of the size, and revenue prospects for, the global market, along with a market share analysis by product type, application, production method, and region/country
Facts and figures pertaining to the market dynamics, technological progress, regulations, prospects, innovations and the impact of various macroeconomic factors
Insights derived from the Porter's Five Forces model, as well as global supply/value chain and PESTLE analyses
An analysis of patents, clinical trials, emerging trends and other developments in the industry
Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and the ESG scores and practices of leading companies
Analysis of the industry structure, including companies' market shares and rankings, strategic alliances, M&A activity and a venture funding outlook
Profiles of leading companies, including Cardinal Health, Lantheus, Curium, GE Healthcare, and Novartis AG

Chapter 1 Executive Summary

Market Outlook
Scope of Report
Market Summary

Chapter 2 Market Overview

Radiopharmaceuticals Overview
Preparation of Radiopharmaceuticals
Macroeconomic Factors Analysis
Porter's Five Forces Analysis
Threat of New Entrants (Moderate to Low)
Threat of Substitutes (Low to Moderate)
Bargaining Power of Suppliers (High)
Bargaining Power of Buyers (Moderate)
Industry Rivalry (Moderate)

Chapter 3 Market Dynamics

Market Drivers
Rising Prevalence of Cancer and Other Chronic Diseases
Unmet Need in Oncology
Precision Medicine
Nuclear Imaging Technologies
Increasing Investment
Market Restraints
Manufacturing and Supply Chain Issues
Infrastructure and Specialized Imaging Equipment Requirements
Shortage of Skilled Professionals
Market Trends
Theranostics
Regional Diversification and Supply Chain Resilience
Opportunities
Radiopharmaceuticals Contract Manufacturing
PET Imaging in AD

Chapter 4 Regulatory Landscape

U.S.
European Union
Japan

Chapter 5 Emerging Technologies and Developments

Emerging Technologies
Ac-225 and Pb-212
Nanoparticle-based Theranostic Agents
Clinical Trials Analysis
Diagnostic Radiopharmaceuticals
Therapeutic Radiopharmaceuticals
Patent Analysis
Key Takeaways

Chapter 6 Market Segmentation Analysis

Segmentation Breakdown
Radiopharmaceuticals Market, by Product Type
Diagnostic Radiopharmaceuticals
Diagnostic Radiopharmaceuticals Market, by Imaging Technique Type
Diagnostic Radiopharmaceuticals Market, by Production Method
Therapeutic Radiopharmaceuticals
Therapeutic Radiopharmaceuticals Market, by Product Type
Radiopharmaceuticals Market by Application
Market Overview
Oncology
Cardiology
Neurology
Others
Radiopharmaceuticals Market by Radioisotope Production Method
Market Overview
Market Revenue and Forecast
Geographic Breakdown
Radiopharmaceuticals Market Breakdown by Region
North America
Europe
Asia-Pacific
RoW

Chapter 7 Competitive Intelligence

Overview
Diagnostic Radiopharmaceuticals
Therapeutic Radiopharmaceuticals

Chapter 8 Sustainability in Radiopharmaceuticals Market: ESG Perspective

Role of ESG in the Radiopharmaceuticals Industry
Environment
Social
Governance
ESG Risk Ratings
Conclusion

Chapter 9 Appendix

Methodology
Sources
Abbreviations
Company Profiles
BAYER AG
BLUE EARTH DIAGNOSTICS
BOSTON SCIENTIFIC CORP.
BWXT MEDICAL LTD.
CARDINAL HEALTH
CURIUM
ECKERT & ZIEGLER
GE HEALTHCARE
INTERNATIONAL ISOTOPES INC.
IONETIX CORP.
JUBILANT PHARMOVA LTD.
LANTHEUS
NMR
NOVARTIS AG
SIEMENS HEATHNIEERS AG
Emerging Start-ups/Market Disruptors

簡介目錄圖表

List of Tables

Summary Table : Global Market for Radiopharmaceuticals, by Region, Through 2029
Table 1 : Porter's Five Forces: Rating Scale
Table 2 : Acquisitions and Funding in Radiopharmaceuticals Market, 2023 and 2024
Table 3 : Selected Diagnostic Radiopharmaceuticals in Development, 2025
Table 4 : Selected Novel Therapeutic Radiopharmaceuticals in Phase 3 Clinical Development, 2025
Table 5 : Number of Patents for Radionuclides, January 2022-December 2024
Table 6 : Number of Patents for Radionuclides, by Radionuclide Type, January 2022-December 2024
Table 7 : Number of Patents for Radionuclides, by Country, January 2022-December 2024
Table 8 : Global Market for Radiopharmaceuticals, by Product Type, Through 2029
Table 9 : Global Market for Diagnostic Radiopharmaceuticals, by Imaging Technique Type, Through 2029
Table 10 : Commercially Available Tc-99m-based Diagnostic Radiopharmaceuticals
Table 11 : Commercially Available I-123-based Diagnostic Radiopharmaceuticals
Table 12 : Commercially Available In-111-based Diagnostic Radiopharmaceuticals
Table 13 : Commercially Available SPECT Radiopharmaceuticals Based on Other Radionuclides
Table 14 : Global Market for SPECT Radiopharmaceuticals, by Radionuclide Type, Through 2029
Table 15 : PET vs. SPECT Radiopharmaceuticals
Table 16 : Commercially Available F-18-based PET Radiopharmaceuticals
Table 17 : Commercially Available Ga-18-based PET Radiopharmaceuticals
Table 18 : Commercially Available Other PET Radiopharmaceuticals
Table 19 : Global Market for PET Radiopharmaceuticals, by Radionuclide Type, Through 2029
Table 20 : Global Market for Diagnostic Radiopharmaceuticals, by Production Method, Through 2029
Table 21 : Common Radionuclide Pairs in Radionuclide Generators
Table 22 : Global Market for Therapeutic Radiopharmaceuticals, by Product Type, Through 2029
Table 23 : Lu- 177-based Therapeutic Radiopharmaceuticals
Table 24 : I-131-based Therapeutic Radiopharmaceuticals
Table 25 : Other Beta-emitter Radioisotope-based Therapeutic Radiopharmaceuticals
Table 26 : Global Market for Beta-emitter Therapeutic Radiopharmaceuticals, by Radionuclide Type, Through 2029
Table 27 : Comparison of Alpha and Beta Particles as Therapeutic Agents
Table 28 : Global Market for Alpha-emitting Therapeutic Radiopharmaceuticals, Through 2029
Table 29 : Global Market for Radiopharmaceuticals, by Application, Through 2029
Table 30 : FDA-approved PET Radiopharmaceuticals for AD Diagnosis
Table 31 : Common Nuclear Reactor-produced Radioisotopes
Table 32 : Common Medical Cyclotron-produced Radioisotopes
Table 33 : Global Market for Radiopharmaceuticals, by Radioisotope Production Method, Through 2029
Table 34 : Global Market for Radiopharmaceuticals, by Region, Through 2029
Table 35 : North American Market for Radiopharmaceuticals, by Product Type, Through 2029
Table 36 : North American Market for Diagnostic Radiopharmaceuticals, by Imaging Technique Type, Through 2029
Table 37 : North American Market for Therapeutics Radiopharmaceuticals, by Product Type, Through 2029
Table 38 : North American Market for Radiopharmaceuticals, by Application, Through 2029
Table 39 : North American Market for Radiopharmaceuticals, by Radioisotope Production Method, Through 2029
Table 40 : North American Market for Radiopharmaceuticals, by Country, Through 2029
Table 41 : European Market for Radiopharmaceuticals, by Product Type, Through 2029
Table 42 : European Market for Diagnostic Radiopharmaceuticals, by Imaging Technique Type, Through 2029
Table 43 : European Market for Therapeutic Radiopharmaceuticals, by Product Type, Through 2029
Table 44 : European Market for Radiopharmaceuticals, by Application, Through 2029
Table 45 : European Market for Radiopharmaceuticals, by Radioisotope Production Method, Through 2029
Table 46 : European Market for Radiopharmaceuticals, by Country, Through 2029
Table 47 : Asia-Pacific Market for Radiopharmaceuticals, by Product Type, Through 2029
Table 48 : Asia-Pacific Market for Diagnostic Radiopharmaceuticals, by Imaging Technique Type, Through 2029
Table 49 : Asia-Pacific Market for Therapeutic Radiopharmaceuticals, by Product Type, Through 2029
Table 50 : Asia-Pacific Market for Radiopharmaceuticals, by Application, Through 2029
Table 51 : Asia-Pacific Market for Radiopharmaceuticals, by Radioisotope Production Method, Through 2029
Table 52 : Asia-Pacific Market for Radiopharmaceuticals, by Country, Through 2029
Table 53 : Number of Cyclotrons Used for Radionuclide Production, by Country, 2025
Table 54 : RoW Market for Radiopharmaceuticals, by Product Type, Through 2029
Table 55 : RoW Market for Diagnostic Radiopharmaceuticals, by Imaging Technique Type, Through 2029
Table 56 : RoW Market for Therapeutic Radiopharmaceuticals, by Product Type, Through 2029
Table 57 : RoW Market for Radiopharmaceuticals, by Application, Through 2029
Table 58 : RoW Market for Radiopharmaceuticals, by Radioisotope Production Method, Through 2029
Table 59 : RoW Market for Radiopharmaceuticals, by Sub-region, Through 2029
Table 60 : ESG Risk Rankings for Radiopharmaceutical Companies, 2025*
Table 61 : Report Sources
Table 62 : Abbreviations Used in This Report
Table 63 : Bayer AG: Company Snapshot
Table 64 : Bayer AG: Financial Performance, FY 2022 and 2023
Table 65 : Bayer AG: Product Portfolio
Table 66 : Bayer AG: News/Key Developments, 2023 and 2024
Table 67 : Blue Earth Diagnostics: Company Snapshot
Table 68 : Blue Earth Diagnostics: Product Portfolio
Table 69 : Blue Earth Diagnostics: News/Key Developments, 2023 and 2024
Table 70 : Boston Scientific Corp.: Company Snapshot
Table 71 : Boston Scientific Corp.: Financial Performance, FY 2023 and 2024
Table 72 : Boston Scientific Corp.: Product Portfolio
Table 73 : BWXT Medical Ltd.: Company Snapshot
Table 74 : BWXT Medical Ltd.: Product Portfolio
Table 75 : BWXT Medical Ltd.: News/Key Developments, 2022-2025
Table 76 : Cardinal Health: Company Snapshot
Table 77 : Cardinal Health: Financial Performance, FY 2022 and 2023
Table 78 : Cardinal Health: Product Portfolio
Table 79 : Cardinal Health: News/Key Developments, 2023 and 2024
Table 80 : Curium: Company Snapshot
Table 81 : Curium: Product Portfolio
Table 82 : Curium: News/Key Developments, 2022-2024
Table 83 : Eckert & Ziegler: Company Snapshot
Table 84 : Eckert & Ziegler: Financial Performance, FY 2022 and 2023
Table 85 : Eckert & Ziegler: Product Portfolio
Table 86 : Eckert & Ziegler: News/Key Developments, 2024 and 2025
Table 87 : GE HealthCare: Company Snapshot
Table 88 : GE HealthCare: Financial Performance, FY 2023 and 2024
Table 89 : GE HealthCare: Product Portfolio
Table 90 : GE HealthCare: News/Key Developments, 2022-2024
Table 91 : International Isotopes Inc.: Company Snapshot
Table 92 : International Isotopes Inc.: Financial Performance, FY 2022 and 2023
Table 93 : International Isotopes Inc.: Product Portfolio
Table 94 : International Isotopes Inc.: News/Key Developments, 2024
Table 95 : IONETIX Corp.: Company Snapshot
Table 96 : IONETIX Corp.: Product Portfolio
Table 97 : IONETIX Corp.: News/Key Developments, 2023 and 2024
Table 98 : Jubilant Pharmova Ltd.: Company Snapshot
Table 99 : Jubilant Pharmova Ltd.: Financial Performance, FY 2022 and 2023
Table 100 : Jubilant Pharmova Ltd.: Product Portfolio
Table 101 : Jubilant Pharmova Ltd.: News/Key Developments, 2023 and 2024
Table 102 : Lantheus: Company Snapshot
Table 103 : Lantheus: Financial Performance, FY 2022 and 2023
Table 104 : Lantheus: Product Portfolio
Table 105 : Lantheus: News/Key Developments, 2022-2025
Table 106 : NMR: Company Snapshot
Table 107 : NMR: Product Portfolio
Table 108 : NMR: News/Key Developments, 2024 and 2025
Table 109 : Novartis AG: Company Snapshot
Table 110 : Novartis AG: Financial Performance, FY 2023 and 2024
Table 111 : Novartis AG: Product Portfolio
Table 112 : Novartis AG: News/Key Developments, 2022-2024
Table 113 : Siemens Healthineers AG: Company Snapshot
Table 114 : Siemens Healthineers AG: Financial Performance, FY 2023 and 2024
Table 115 : Siemens Healthineers AG: Product Portfolio
Table 116 : Siemens Healthineers AG: News/Key Developments, 2023 and 2024
Table 117 : List of Few Emerging Startups/ Market Disruptors

List of Figures

Summary Figure : Global Market Shares of Radiopharmaceuticals, by Region, 2023
Figure 1 : Porter's Five Forces Analysis
Figure 2 : Radiopharmaceuticals Market Dynamics
Figure 3 : Estimated New Cancer Cases, 2022-2050
Figure 4 : Global Cancer Incidence, by Region, 2022 vs. 2045
Figure 5 : Number of Active Clinical Trials for Diagnostic Radiopharmaceuticals, by Radioisotope Type, 2025
Figure 6 : Number of Active Clinical Trials for Therapeutic Radiopharmaceuticals, by Radioisotope Type, 2025
Figure 7 : Global Market Shares of Radiopharmaceuticals, by Product Type, 2023
Figure 8 : Global Market Shares of Diagnostic Radiopharmaceuticals, by Imaging Technique Type, 2023
Figure 9 : Global Market Shares of SPECT Radiopharmaceuticals, by Radionuclide Type, 2023
Figure 10 : Global Market Shares of PET Radiopharmaceuticals, by Radionuclide Type, 2023
Figure 11 : Global Market Shares of Diagnostic Radiopharmaceuticals, by Production Method, 2023
Figure 12 : Global Market Shares of Therapeutic Radiopharmaceuticals, by Product Type, 2023
Figure 13 : Global Market Shares of Beta-emitter Therapeutic Radiopharmaceuticals, by Radionuclide Type, 2023
Figure 14 : Global Market Shares of Radiopharmaceuticals, by Application, 2023
Figure 15 : Global Market Shares of Radiopharmaceuticals, by Radioisotope Production Method, 2023
Figure 16 : Global Market Shares of Radiopharmaceuticals, by Region, 2023
Figure 17 : North American Market Shares of Radiopharmaceuticals, by Product Type, 2023
Figure 18 : North American Market Shares of Diagnostic Radiopharmaceuticals, by Imaging Technique Type, 2023
Figure 19 : North American Market Shares of Therapeutic Radiopharmaceuticals, by Product Type, 2023
Figure 20 : North American Market Shares of Radiopharmaceuticals, by Application, 2023
Figure 21 : North American Market Shares of Radiopharmaceuticals, by Radioisotope Production Method, 2023
Figure 22 : North American Market Shares of Radiopharmaceuticals, by Country, 2023
Figure 23 : European Market Shares of Radiopharmaceuticals, by Product Type, 2023
Figure 24 : European Market Shares of Diagnostic Radiopharmaceuticals, by Imaging Technique Type, 2023
Figure 25 : European Market Shares of Therapeutic Radiopharmaceuticals, by Product Type, 2023
Figure 26 : European Market Shares of Radiopharmaceuticals, by Application, 2023
Figure 27 : European Market Shares of Radiopharmaceuticals, by Radioisotope Production Method, 2023
Figure 28 : European Market Shares of Radiopharmaceuticals, by Country, 2023
Figure 29 : Asia-Pacific Market Shares of Radiopharmaceuticals, by Product Type, 2023
Figure 30 : Asia-Pacific Market Shares of Diagnostic Radiopharmaceuticals, by Imaging Technique Type, 2023
Figure 31 : Asia-Pacific Market Shares of Therapeutic Radiopharmaceuticals, by Product Type, 2023
Figure 32 : Asia-Pacific Market Shares of Radiopharmaceuticals, by Application, 2023
Figure 33 : Asia-Pacific Market Shares of Radiopharmaceuticals, by Radioisotope Production Method, 2023
Figure 34 : Asia-Pacific Market Shares of Radiopharmaceuticals, by Country, 2023
Figure 35 : RoW Market Shares of Radiopharmaceuticals, by Product Type, 2023
Figure 36 : RoW Market Shares of Diagnostic Radiopharmaceuticals, by Imaging Technique Type, 2023
Figure 37 : RoW Market Shares of Therapeutic Radiopharmaceuticals, by Product Type, 2023
Figure 38 : RoW Market Shares of Radiopharmaceuticals, by Application, 2023
Figure 39 : RoW Market Shares of Radiopharmaceuticals, by Radioisotope Production Method, 2023
Figure 40 : RoW Market Shares of Radiopharmaceuticals, by Sub-Region, 2023
Figure 41 : Global Market Shares of Diagnostic Radiopharmaceuticals, by Company, 2023
Figure 42 : Global Market Shares of Therapeutic Radiopharmaceuticals, by Company, 2023
Figure 43 : Bayer AG: Revenue Shares, by Business Unit, FY 2023
Figure 44 : Bayer AG: Revenue Shares, by Country/Region, FY 2023
Figure 45 : Boston Scientific Corp.: Revenue Shares, by Business Unit, FY 2024
Figure 46 : Boston Scientific Corp.: Revenue Shares, by Country/Region, FY 2024
Figure 47 : Cardinal Health: Revenue Shares, by Business Unit, FY 2023
Figure 48 : Cardinal Health: Revenue Shares, by Country/Region, FY 2023
Figure 49 : Cardinal Health: Revenue Shares, by Country/Region, FY 2023
Figure 50 : Eckert & Ziegler: Revenue Shares, by Country/Region, FY 2023
Figure 51 : GE HealthCare: Revenue Shares, by Business Unit, FY 2024
Figure 52 : GE HealthCare: Revenue Shares, by Country/Region, FY 2024
Figure 53 : International Isotopes Inc.: Revenue Shares, by Business Unit, FY 2023
Figure 54 : International Isotopes Inc.: Revenue Shares, by Country/Region, FY 2023
Figure 55 : Jubilant Pharmova Ltd.: Revenue Shares, by Business Unit, FY 2023
Figure 56 : Jubilant Pharmova Ltd.: Revenue Shares, by Country/Region, FY 2023
Figure 57 : Lantheus: Revenue Shares, by Business Unit, FY 2023
Figure 58 : Novartis AG: Revenue Shares, by Business Unit, FY 2024
Figure 59 : Novartis AG: Revenue Shares, by Country/Region, FY 2024
Figure 60 : Siemens Healthineers AG: Revenue Shares, by Business Unit, FY 2024
Figure 61 : Siemens Healthineers AG: Revenue Shares, by Country/Region, FY 2024